Profile data is unavailable for this security.
About the company
4DMedical Limited is an Australia-based medical technology company. Through its flagship patented XV Technology, the Company enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers its FDA-cleared XV Lung Ventilation Analysis Software (XV LVA), which is a modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS. XV LVAS and CT LVAS reports are prepared using the Company’s software as a service (SaaS) delivery model using existing hospital imaging equipment or the Company's XV Scanner. It initiated the commercial rollout of XV LVAS with I-MED Radiology Network (I-MED), which is a diagnostic imaging provider with approximately 250 clinics nationwide. The Company provides its lung imaging technology to other selected clinics across the I-MED network.
- Revenue in AUD (TTM)1.03m
- Net income in AUD-30.83m
- Incorporated2012
- Employees--
- Location4DMedical LtdLevel 7 Melbourne Connect700 Swanston StreetMELBOURNE 3053AustraliaAUS
- Phone+61 39545-5940
- Websitehttps://4dmedical.com/
Mergers & acquisitions
| Acquired company | 4DX:ASX since announced | Transaction value |
|---|---|---|
| Imbio LLC | -39.47% | 69.30m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ImpediMed Ltd | 10.47m | -19.42m | 143.64m | 76.00 | -- | 2.82 | -- | 13.72 | -0.0102 | -0.0102 | 0.0055 | 0.0252 | 0.1961 | 1.32 | 4.41 | 137,802.60 | -36.37 | -52.27 | -40.94 | -62.34 | 86.95 | 80.64 | -185.47 | -264.76 | 6.85 | -- | 0.0244 | -- | 7.36 | 27.87 | -3.26 | -- | 37.83 | -- |
| Mach7 Technologies Ltd | 26.97m | -5.55m | 161.63m | 90.00 | -- | 2.97 | 74.68 | 5.99 | -0.0231 | -0.0231 | 0.1123 | 0.2256 | 0.3605 | -- | 3.21 | -- | -7.42 | -7.48 | -8.73 | -8.65 | 95.09 | 93.72 | -20.59 | -20.56 | -- | -2,605.17 | 0.0193 | -- | 10.97 | 28.30 | 74.85 | -- | 29.28 | -- |
| Cyclopharm Limited | 32.21m | -4.70m | 162.41m | 87.00 | -- | 4.38 | -- | 5.04 | -0.0508 | -0.0508 | 0.3476 | 0.3428 | 0.6748 | 1.11 | 4.13 | 370,173.10 | -9.85 | -12.60 | -11.92 | -14.94 | 68.15 | 70.20 | -14.60 | -25.47 | 2.32 | -18.40 | 0.1159 | -- | 11.22 | 15.50 | 28.90 | -- | -7.83 | -12.94 |
| EMvision Medical Devices Ltd | 8.86m | -3.22m | 172.56m | -- | -- | 27.58 | -- | 19.47 | -0.0449 | -0.0449 | 0.1186 | 0.0733 | 0.7954 | -- | -- | -- | -28.95 | -67.20 | -45.25 | -79.38 | -- | -- | -36.40 | -175.99 | -- | -35.20 | 0.3424 | -- | 62.08 | 70.47 | 36.64 | -- | -- | -- |
| Genetic Signatures Ltd | 16.49m | -18.04m | 179.31m | -- | -- | 3.34 | -- | 10.87 | -0.1245 | -0.1245 | 0.1136 | 0.2172 | 0.3366 | 1.06 | 5.25 | -- | -36.81 | -7.14 | -40.19 | -7.82 | 40.66 | 57.68 | -109.38 | -13.74 | 5.95 | -18,040.00 | 0.0003 | -- | -38.11 | 33.44 | -558.77 | -- | 73.20 | -- |
| Aroa Biosurgery Ltd | 63.51m | -9.77m | 211.69m | 261.00 | -- | 2.42 | -- | 3.33 | -0.0284 | -0.0284 | 0.1847 | 0.2536 | 0.607 | 1.56 | 2.82 | -- | -9.34 | -10.37 | -10.11 | -12.52 | 85.39 | 80.63 | -15.39 | -20.31 | 6.40 | -- | 0.0726 | -- | 9.01 | 24.26 | -2,583.84 | -- | 33.65 | -- |
| 4DMedical Ltd | 1.03m | -30.83m | 225.05m | -- | -- | 2.47 | -- | 219.51 | -0.0882 | -0.0882 | 0.0029 | 0.2332 | 0.0098 | 0.092 | 0.1585 | -- | -29.47 | -43.96 | -39.07 | -57.58 | 95.00 | 32.30 | -3,007.64 | -2,704.36 | 1.79 | -- | 0.0476 | -- | -31.84 | -1.86 | -27.92 | -- | 2.46 | -- |
| EBR Systems Inc | 0.00 | -52.66m | 301.95m | -- | -- | 6.45 | -- | -- | -0.1817 | -0.1817 | 0.00 | 0.152 | 0.00 | -- | -- | -- | -46.54 | -- | -50.70 | -- | -- | -- | -- | -- | -- | -28.66 | 0.5609 | -- | -- | -- | -5.89 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Perennial Value Management Ltd.as of 22 Dec 2022 | 14.70m | 3.76% |
| Netwealth Investments Ltd.as of 16 Aug 2023 | 2.34m | 0.60% |
| BetaShares Capital Ltd.as of 31 May 2024 | 598.14k | 0.15% |
| DFA Australia Ltd.as of 31 May 2024 | 211.40k | 0.05% |
| Dimensional Fund Advisors LPas of 06 Jun 2024 | 54.14k | 0.01% |
| American Century Investment Management, Inc.as of 05 Jun 2024 | 2.41k | 0.00% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 0.00 | 0.00% |
